DexCom, Inc. (NASDAQ:DXCM) EVP Sells $45,346.60 in Stock

DexCom, Inc. (NASDAQ:DXCM) EVP Michael Jon Brown sold 652 shares of DexCom stock in a transaction that occurred on Wednesday, July 31st. The stock was sold at an average price of $69.55, for a total transaction of $45,346.60. Following the completion of the transaction, the executive vice president now directly owns 66,249 shares in the company, valued at approximately $4,607,617.95. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Michael Jon Brown also recently made the following trade(s):

• On Friday, June 28th, Michael Jon Brown sold 659 shares of DexCom stock. The shares were sold at an average price of $114.29, for a total transaction of $75,317.11.
• On Friday, May 31st, Michael Jon Brown sold 652 shares of DexCom stock. The stock was sold at an average price of $119.24, for a total transaction of $77,744.48.

DexCom Price Performance

NASDAQ:DXCM traded up $2.50 during mid-day trading on Thursday, hitting $70.32. 11,190,289 shares of the company’s stock traded hands, compared to its average volume of 3,571,464. The company has a debt-to-equity ratio of 1.00, a quick ratio of 2.48 and a current ratio of 2.82. The firm’s 50 day simple moving average is $111.54 and its 200 day simple moving average is $122.55. DexCom, Inc. has a 1 year low of $62.34 and a 1 year high of $142.00. The company has a market cap of $28.18 billion, a PE ratio of 43.76, a price-to-earnings-growth ratio of 2.16 and a beta of 1.16.

DexCom (NASDAQ:DXCM) last released its quarterly earnings results on Thursday, July 25th. The medical device company reported $0.43 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.39 by $0.04. DexCom had a net margin of 16.95% and a return on equity of 31.41%. The company had revenue of $1 billion for the quarter, compared to analysts’ expectations of $1.04 billion. During the same period last year, the company earned $0.34 EPS. The firm’s revenue for the quarter was up 15.3% compared to the same quarter last year. Sell-side analysts expect that DexCom, Inc. will post 1.69 EPS for the current year.

Analysts Set New Price Targets

A number of equities analysts have weighed in on the stock. Raymond James upped their price objective on shares of DexCom from $151.00 to $160.00 and gave the stock a “strong-buy” rating in a research report on Friday, April 26th. Oppenheimer lowered their target price on shares of DexCom from $150.00 to $115.00 and set an “outperform” rating for the company in a research note on Friday, July 26th. Morgan Stanley lowered their price objective on shares of DexCom from $120.00 to $75.00 and set an “equal weight” rating for the company in a research note on Friday, July 26th. Baird R W lowered shares of DexCom from a “strong-buy” rating to a “hold” rating in a research note on Friday, July 26th. Finally, Wells Fargo & Company lowered their price objective on shares of DexCom from $145.00 to $80.00 and set an “overweight” rating for the company in a research note on Friday, July 26th. Seven equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $111.50.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. Crewe Advisors LLC purchased a new position in DexCom in the first quarter valued at approximately $29,000. Migdal Insurance & Financial Holdings Ltd. acquired a new position in DexCom in the second quarter worth $25,000. DSM Capital Partners LLC bought a new stake in DexCom in the fourth quarter valued at $28,000. Riverview Trust Co bought a new stake in DexCom in the first quarter valued at $32,000. Finally, Valley National Advisers Inc. lifted its stake in DexCom by 73.0% in the fourth quarter. Valley National Advisers Inc. now owns 244 shares of the medical device company’s stock valued at $30,000 after buying an additional 103 shares during the last quarter. 97.75% of the stock is currently owned by hedge funds and other institutional investors.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.